Resources

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL

The Chancellor’s Autumn Budget placed life sciences at the forefront of the UK’s growth agenda, providing key support for R&D tax relief, medicines manufacturing, and sector-specific financing through the British Business Bank.

Read today's blog to learn about our latest reports, upcoming events and our CEO's thoughts on the upcoming budget.

tranScrip is delighted to announce the appointment of Roz Sutton as Senior Director of Regulatory Affairs

In this blog, Izzy Webb outlines why the UK has published voluntary guidance to promote synthetic nucleic acid screening and who the guidance is intended for.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.

The political party conference season is in full swing, and the BIA is out in force in Liverpool for the Labour Party conference this week. I'm heartened to see the focus in ministerial speeches and the fringe on topics close to our hearts. Read on for updates on the Lib Dem conference, West Streeting speech and Invest in Women Taskforce.

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

In the final piece of the 'AI in life sciences' series, Jenny Yu, Marsh’s Life Sciences industry practice leader and experts from law firm Kennedys emphasize essential steps for life sciences companies to develop and implement a successful AI business strategy. They delve into effective management of outcomes from AI technologies and strategies to mitigate potential risks.

Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

BIA Future of UK Regulation Conference 2023: Novel technologies